Detail akcie arGEN-X SpADR online

Business Summary: argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, argenx SE - ADR revenues increased 97% to $2.87B. Net income increased from $58.9M to $759.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Foreign Exchange Gain/Loss–Non-Business increase from $6.7M to $74.2M (income), Other Operating Income increase of 53% to $59.7M (income).